Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Johnson & Johnson
IndexDJIA S&P500 P/E17.68 EPS (ttm)6.04 Insider Own0.01% Shs Outstand2.80B Perf Week0.08%
Market Cap298.97B Forward P/E17.28 EPS next Y6.18 Insider Trans0.72% Shs Float2.80B Perf Month-1.22%
Income17.32B PEG2.73 EPS next Q1.26 Inst Own67.50% Short Float0.91% Perf Quarter-0.45%
Sales74.43B P/S4.02 EPS this Y24.60% Inst Trans-0.52% Short Ratio3.10 Perf Half Y2.81%
Book/sh27.21 P/B3.93 EPS next Y3.69% ROA16.50% Target Price108.29 Perf Year18.49%
Cash/sh11.79 P/C9.06 EPS next 5Y6.47% ROE28.90% 52W Range83.76 - 108.99 Perf YTD19.85%
Dividend2.80 P/FCF43.18 EPS past 5Y1.00% ROI15.00% 52W High-2.00% Beta0.57
Dividend %2.62% Quick Ratio2.20 Sales past 5Y2.30% Gross Margin69.30% 52W Low27.51% ATR1.56
Employees128100 Current Ratio2.60 Sales Q/Q5.10% Oper. Margin32.80% RSI (14)54.67 Volatility2.03% 1.34%
OptionableYes Debt/Eq0.20 EPS Q/Q61.20% Profit Margin29.60% Rel Volume1.43 Prev Close104.07
ShortableYes LT Debt/Eq0.17 EarningsJan 19 BMO Payout34.80% Avg Volume8.22M Price106.81
Recom2.40 SMA20-0.06% SMA501.65% SMA2005.37% Volume11,729,823 Change2.63%
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
Dec-12-11Reiterated UBS Buy $72 → $69
Dec-18-14 10:53AM  BTG's Dame Louise Makin builds fast-growing healthcare group at Financial Times
Dec-17-14 12:08PM  3 stocks to buy in a market crash at
10:00AM  Johnson & Johnson to Host Fourth-Quarter/Full-Year 2014 Investor Conference Call on Results PR Newswire
Dec-16-14 04:22PM  Sexually Active? How Much Do You Drink? Your Workplace Health Records May Not Be as Private as You Think Bloomberg
03:05PM  Sexually Active? How Much Do You Drink? Your Workplace Health Records May Not Be as Private as You Think at Bloomberg
Dec-15-14 10:04AM  Is This The Future Of Late-Stage Drug Development? at Forbes
Dec-11-14 06:39PM  J&J Tuberculosis Drug Poised for Expanded Reach at The Wall Street Journal
02:41PM  Boston Scientific Lost the First Place in Innovation Gurufocus
10:29AM  $300 mln pledged to buy Ebola vaccines as NewLink shot hits snag Reuters
02:00AM  One shot or two? Many questions unresolved in Ebola vaccine race Reuters
Dec-10-14 08:46AM  APAC Joint Replacement Market to Reach $6.4 Billion by 2020 PR Newswire
Dec-09-14 05:45PM  Covidien Loses $176M Award in Patent Case Against JNJ Unit Zacks
02:57PM  Stop Waiting for Johnson & Johnson To Break Up or Down Yahoo Finance Blogs
12:28PM  The Dollar and the Damage Done at
10:53AM  U.S. agency offers legal immunity to Ebola vaccine makers Reuters
Dec-08-14 06:39PM  Top Global Stocks: Jazz, Actavis In IBD's World List at Investor's Business Daily
05:50PM  Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Zacks
Dec-05-14 12:36PM  New ETF For Environmentalists Benzinga
11:51AM  Stocks Hold Small Gains; Taser Hits New High at Investor's Business Daily
Dec-04-14 06:20AM  Ebola, Ethics, And The New Normal Of Scary Germs at Forbes
Dec-03-14 06:40PM  Johnson & Johnson Investor's Business Daily
12:26PM  Wednesday's midday movers: Apple, Kraft & more at CNBC
11:02AM  Exclusive: J&J hires Goldman to explore sale of Splenda - sources Reuters
11:00AM  Alzheimer's drug shows promise CNBC
Dec-02-14 05:18PM  Early Tests Go Well For Biogen's Drug To Slow Alzheimer's Investor's Business Daily
05:05PM  Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU Zacks
12:23PM  Biogen Alzheimer's Drug Succeeding In Early Tests at Investor's Business Daily
Dec-01-14 10:09AM  Australian Diabetes Management Market and Diabetes Diagnostic Devices Market Spurted by $46 Million Between 2005 and 2013 PR Newswire
Nov-27-14 12:20PM  Johnson & Johnson's Rezolsta Approved in the EU for HIV-1 Zacks
Nov-26-14 04:30PM  AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study Zacks
03:16PM  Spanx for Your Face at BusinessWeek
02:49PM  Health Care ETFs Healthy on a Global Basis, Too ETF Trends
08:49AM  Apple eyes holiday sales CNBC
Nov-25-14 12:01PM  Apple breaks $700 billion CNBC
05:00AM  More Medicine Goes Off Limits in Drug-Price Showdown Bloomberg
05:00AM  More Medicine Goes Off Limits in Drug-Price Showdown at Bloomberg
Nov-24-14 05:24PM  It was another slow, low volume, lackluster trading session Yahoo Finance Blogs
03:57PM  Merck, Iowa firm sign Ebola vaccine licensing deal AP
11:08AM  FDA tightens guidelines on technique for uterine fibroid surgery Reuters
Nov-22-14 05:00AM  Motley Fool: Pundits pandering your wealth away at USA TODAY
12:20AM  On Solid Ground at
Nov-21-14 04:31PM  JOHNSON & JOHNSON Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
03:50PM  Market getting a little toppy: Pro CNBC
12:47PM  Is The US Stock Market Unhealthy? at Forbes
Nov-20-14 04:00PM  Dow, S&P close at records; Intel up 4% at CNBC
03:45PM  J&J Seeks FDA Approval for Schizophrenia Treatment Zacks
01:03PM  J&J demands $7.2 bln from Boston Scientific as trial begins Reuters
11:36AM  The bond market doesn't care about improving data at CNBC
09:59AM  Inflation Low? Not If Youre Investing For Long Haul YCharts
12:01AM  J&J Seeks Billions in Trial Over Decade-Old Guidant Bidding War at Bloomberg
Nov-19-14 08:20PM  Johnson & Johnson Partners with Save the Children to Help Millions of Children over the Next Three Years PR Newswire
05:35PM  Mallinckrodt Q4 Earnings Beat Views, But Outlook Hazy at Investor's Business Daily
04:55PM  The rise of the social entrepreneur CNBC
11:42AM  Mallinckrodt Earnings Beat But No New Guidance at Investor's Business Daily
09:00AM  Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate PR Newswire
Nov-18-14 03:21PM  J&J Said to Boost Bond Sale as Investors Chase AAA Debt at Bloomberg
09:10AM  Companies Spending the Most on R&D 24/7 Wall St.
Nov-17-14 05:10PM  Covidien's Test Data Positive for VenaSeal Closure System Zacks
04:40PM  The 10 biggest R&D spenders worldwide at Fortune
03:58PM  Incyte Building Blockbuster Drug One Disease At A Time at Investor's Business Daily
Nov-16-14 04:45PM  Big Study Looks At Length of Drug Treatment After Stent Implantation at Forbes
Nov-14-14 11:35AM  What Licensing Imetelstat Will Mean for Geron at 24/7 Wall St.
09:41AM  US STOCKS-Wall St opens flat after retail sales, UMich data on tap Reuters
08:13AM  US STOCKS-Futures flat ahead of retail sales, UMich data Reuters
07:34AM  US STOCKS-Futures little changed ahead of data Reuters
Nov-13-14 06:27PM  Geron sells last drug in pipeline to J&J unit Reuters
04:34PM  Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson at TheStreet
04:17PM  Miami jury begins deliberations in Boston Scientific mesh trial Reuters
03:27PM  How Did Medical Device Makers Become Poster Children for Obamacare Critics? at Forbes
09:17AM  [$$] Mallinckrodt Says FDA Reclassified ADHD Generic Drug at The Wall Street Journal
08:31AM  Is A Boston University Professor's Plan For Lower Drug Costs Viable? at Forbes
Nov-12-14 01:42PM  Europe remains the risk: Trader CNBC
12:28PM  What Johnson & Johnson's 'Chart Watchers' Need To Know Benzinga
Nov-11-14 04:52PM  Amgen psoriasis drug tops J&J's Stelara in Phase III study Reuters
03:45PM  Dendreon Shares Plummet After It Files for Bankruptcy Zacks
01:09PM  Impact of US-China trade deal CNBC
08:09AM  What do Carl Icahn, Bill Gross and Charlie Munger have in common? Yahoo Finance
Nov-10-14 10:50PM  [$$] Johnson & Johnson Seeks Acquisitions in China at The Wall Street Journal
07:40PM  CORRECTING and REPLACING Biosense Webster Teams Up with to Challenge Americans to Get SMART About AfibSM Business Wire
07:00PM  Cramer: This stock has years of upside CNBC
06:00PM  Cramer: Default to big themes CNBC
04:19PM  JOHNSON & JOHNSON Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:54PM  DexCom G4 Platinum Software Gains FDA Nod, Shares Surge Zacks
10:38AM  Dendreon files bankruptcy protection CNBC
09:30AM  Ebola Contracts Worth $2 Billion Could Benefit Drugmakers at Bloomberg
08:34AM  The Inaccurate And Unfair WHO Attack On Pharma Ebola Efforts at Forbes
03:51AM  October jitters are just a taste things to come at Financial Times
03:09AM  [$$] J&J Seeks Acquisitions in China at The Wall Street Journal
Nov-09-14 10:06PM  Johnson & Johnson: China is still our top market CNBC
Nov-07-14 04:05PM  Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition PR Newswire
11:28AM  Shampoo to start-ups: J&J joins tech frenzy at CNBC
06:38AM  Johnson & Johnson buys energy drink brand in India Reuters
04:30AM  US earnings boost masks revenue fears at Financial Times
Nov-06-14 05:48PM  J&J Snack Foods posts 4Q profit AP
04:55PM  Daily Market Recap... Yahoo Finance Blogs
04:15PM  Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting Marketwired
01:04PM  JOHNSON & JOHNSON Financials EDGAR Online Financials
12:01AM  Teva, Hallmark, Bees, Pirate Bay: Intellectual Property at Bloomberg
Nov-05-14 05:46PM  The Thorns, Roses, All Time Highs, and ETF All Time Highs... Yahoo Finance Blogs
04:52PM  J&J Wins U.S. Approval for Hepatitis C Combo With Gilead at Bloomberg
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women's health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON'S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM
Caruso Dominic JVP, Finance; CFOAug 21Option Exercise66.1830,0001,985,40091,600Aug 25 04:35 PM
Caruso Dominic JVP, Finance; CFOAug 21Sale104.3030,0003,129,06961,600Aug 25 04:35 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Option Exercise66.1822,0001,455,960112,294May 06 06:10 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Sale100.0522,0002,201,10090,294May 06 06:10 PM
JOHNSON & JOHNSON10% OwnerMay 01Option Exercise5.1672,690375,0801,773,730May 05 02:19 PM
COSGROVE STEPHEN JCorporate ControllerApr 25Option Exercise66.181,51099,93291,293Apr 28 05:03 PM
Fasolo PeterVP, Global Human ResourcesMar 14Sale93.156,824635,64015,647Mar 17 06:10 PM
Fasolo PeterVP, Global Human ResourcesMar 04Option Exercise62.6644,8612,811,19243,571Mar 05 06:18 PM
Ullmann Michael HVP, General CounselJan 10Option Exercise0.009,265065,448Jan 14 06:15 PM
Stoffels PaulusChief Scientific OfficerJan 10Option Exercise0.0018,690035,603Jan 14 06:03 PM
Gorsky AlexChairman, CEOJan 10Option Exercise0.0012,058081,579Jan 14 06:01 PM
Fasolo PeterVP, Worldwide Human ResourcesJan 10Option Exercise0.002,58809,310Jan 14 06:00 PM
COSGROVE STEPHEN JCorporate ControllerJan 10Option Exercise0.002,645090,804Jan 14 05:58 PM
Caruso Dominic JVP, Finance; CFOJan 10Option Exercise0.0012,121065,656Jan 14 05:56 PM